Log in
NASDAQ:ICCC

ImmuCell Stock Forecast, Price & News

$5.65
+0.39 (+7.41 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.27
Now: $5.65
$5.65
50-Day Range
$4.98
MA: $5.40
$5.92
52-Week Range
$3.70
Now: $5.65
$8.13
Volume24,977 shs
Average Volume45,530 shs
Market Capitalization$40.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.72 million
Cash Flow$0.15 per share
Book Value$4.02 per share

Profitability

Net Income$-1,300,000.00

Miscellaneous

Employees47
Market Cap$40.75 million
Next Earnings Date11/9/2020 (Estimated)
OptionableNot Optionable
$5.65
+0.39 (+7.41 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

How has ImmuCell's stock price been impacted by Coronavirus (COVID-19)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICCC stock has increased by 31.4% and is now trading at $5.65.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ImmuCell?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ImmuCell
.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for ImmuCell
.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) posted its quarterly earnings results on Wednesday, August, 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The biotechnology company earned $2.97 million during the quarter. ImmuCell had a negative net margin of 11.75% and a negative return on equity of 5.89%.
View ImmuCell's earnings history
.

What price target have analysts set for ICCC?

1 brokerages have issued 12-month price targets for ImmuCell's stock. Their forecasts range from $14.00 to $14.00. On average, they expect ImmuCell's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 147.8% from the stock's current price.
View analysts' price targets for ImmuCell
.

Are investors shorting ImmuCell?

ImmuCell saw a drop in short interest in August. As of August 31st, there was short interest totaling 6,400 shares, a drop of 46.2% from the August 15th total of 11,900 shares. Based on an average daily trading volume, of 20,200 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold.
View ImmuCell's Short Interest
.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Biocept (BIOC), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Novavax (NVAX) and Verastem (VSTM).

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perritt Capital Management Inc. (0.83%), RBF Capital LLC (0.18%), Flagship Harbor Advisors LLC (0.17%) and Ingalls & Snyder LLC (0.14%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends for ImmuCell
.

Which institutional investors are selling ImmuCell stock?

ICCC stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, and Perritt Capital Management Inc..
View insider buying and selling activity for ImmuCell
.

Which institutional investors are buying ImmuCell stock?

ICCC stock was acquired by a variety of institutional investors in the last quarter, including RBF Capital LLC, and Flagship Harbor Advisors LLC. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche.
View insider buying and selling activity for ImmuCell
.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $5.65.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $40.75 million and generates $13.72 million in revenue each year. The biotechnology company earns $-1,300,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. ImmuCell employs 47 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.